Patent US4877806A successfully refreshed from Google Patents.
US4877806A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of tricyclodecene-3,4,7,8-tetracarboxylic acid derivatives as anti-murine tumor agents
Assignee: Chevron USA Inc
•
Filing: 1988-03-18
•
Granted: 1989-10-31
•
Expires: 2008-03-18
Abstract
Abstract The method which comprises administering to a tumor-containing animal derivatives of tricyclodecene-3,4,7,8-tetracarboxylic acid derivatives, preferably a compound having the following structural formula: ##STR1## or a pharmaceutically acceptable salt thereof.
Inventors
- 👤 Ralph P. Neighbors
- 👤 Joseph R. Riden
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 03:29
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
42 words
A method of treating mammals afflicted with murine tumors comprising administering to said mammals in a therapeutically effective amount sufficient to increase survival time or inhibit tumor growth the diimide of tricyclo[4.2.2.0 2 .5 ]dec-9-ene-3,4,7,8-tetracarboxylic acid or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
42 words
A method of treating mammals afflicted with murine tumors comprising administering to said mammals in a therapeutically effective amount sufficient to increase survival time or inhibit tumor growth the diimide of tricyclo[4.2.2.0 2 .5 ]dec-9-ene-3,4,7,8-tetracarboxylic acid or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
47 words
A therapeutic composition for treating murine tumors comprising a therapeutically effective amount sufficient to increase survival time or inhibit tumor growth of the diimide of tricyclo[4.2.2.0 2 .5 ]dec-9-ene-3,4,7,8-tetracarboxylic acid, or a pharmaceutically acceptable salt thereof, as an active ingredient and a pharmaceutically acceptable additive or carrier.
Claim 4
Dependent Claim
47 words
A therapeutic composition for treating murine tumors comprising a therapeutically effective amount sufficient to increase survival time or inhibit tumor growth of the diimide of tricyclo[4.2.2.0 2 .5 ]dec-9-ene-3,4,7,8-tetracarboxylic acid, or a pharmaceutically acceptable salt thereof, as an active ingredient and a pharmaceutically acceptable additive or carrier.
References Cited (Backward Citations)
US4670461A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-10-30 | 1993-05-01 | 1993-10-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-10-30 | 1997-05-01 | 1997-10-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-10-30 | 2001-05-01 | 2001-10-31 | $7700.00 | Window Closed / Lapsed |